Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE

Standard Dose
50MG;500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 210542 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - 50MG;500MG Sponsor ZYDUS PHARMS USA INC Submission history Latest submission status date: 2023-02-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 210542 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - 50MG;500MG Sponsor ZYDUS PHARMS USA INC Submission history Latest submission status date: 2023-02-16 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.